SYNTAX

DNA Script to Unveil Industry’s Most Versatile On-site, On-Demand DNA Printer at the World’s Largest Synthetic Biology Conference

Retrieved on: 
Monday, May 22, 2023
Hardware, Data Management, Other Health, Technology, Nanotechnology, Medical Devices, Genetics, Agriculture, Natural Resources, Biotechnology, Science, Software, Other Science, Research, Health, Medical Supplies, Columbia University, DNA, Public affairs, Workflow, EDS, Enzyme, Multimedia, Genomics, Doctor of Philosophy, Associate, Synthetic biology, SYNTAX, Laboratory, Biology, ESG, Conference, Imperial College London, Script, Structure, Fine chemical, Typesetting, Vaccine

The company will unveil the new platform during the upcoming global SynBioBeta 2023 Conference.

Key Points: 
  • The company will unveil the new platform during the upcoming global SynBioBeta 2023 Conference.
  • “A major bottleneck in executing synthetic biology workflows is the time delay in obtaining synthetic DNA from commercial suppliers,” said Paul Freemont, PhD, Head of Structural and Synthetic Biology and the London Biofoundry at Imperial College London.
  • “The new STX-200 system is the next step in our quest to make biology programmable,” said Thomas Ybert, PhD, CEO and co-founder of DNA Script.
  • DNA Script representatives will showcase the new SYNTAX platform in booth #16 at the SynBioBeta 2023 Conference in Oakland, Calif. on May 23-25, 2023.

DNA Script Extends Distributorships to Middle East to Expand Access to Same-day Enzymatic DNA Synthesis

Retrieved on: 
Wednesday, October 12, 2022
Health, Genetics, Other Science, General Health, Research, Science, Biotechnology, Genomics, APAC, Synthetic biology, SYNTAX, Research, EDS, Technology, Industry, NGS, Organic acid, CRISPR, Enzyme, DNA, Script, Vaccine, Fine chemical, KSA

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has signed distribution agreements in the Middle East with Gulf Scientific Corporation (Bahrain, KSA, Kuwait, Oman, Qatar and UAE) and Eisenberg Ltd. (Israel) to expand its worldwide footprint of sales, service and support.

Key Points: 
  • DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has signed distribution agreements in the Middle East with Gulf Scientific Corporation (Bahrain, KSA, Kuwait, Oman, Qatar and UAE) and Eisenberg Ltd. (Israel) to expand its worldwide footprint of sales, service and support.
  • Like APAC, the Middle East is experiencing significant genomic research growth with increased demand for synthetic biology tools.
  • The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System.
  • By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.

French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats

Retrieved on: 
Tuesday, June 28, 2022
Science, Biotechnology, Defense, Research, Health, Infectious Diseases, Genetics, Government Technology, Hybridization probe, Enzyme, View, Weapon, CEO, Research, Armed Forces DNA Identification Laboratory, EDS, DGA, Organic acid, Partnership, Technology, Military, DNA, Real-time, SYNTAX, Infection, Fine chemical

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the companys SYNTAX System DNA printer.

Key Points: 
  • DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the companys SYNTAX System DNA printer.
  • This success was achieved as part of a contract with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), first announced in January 2021.
  • The partnership leverages the SYNTAX System to produce high-quality DNA primers and probes to rapidly develop qPCR assays for infectious disease detection.
  • This extension validates the importance of our SYNTAX benchtop DNA printing system for rapid response programs, said Thomas Ybert, CEO and co-founder of DNA Script.

DNA Script Enables Same-day q/dPCR from Design to Results with Launch of Next-generation SYNTAX Kits at AGBT

Retrieved on: 
Monday, June 6, 2022
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Science, DC3, NGS, EDS, Conference, Research, CTO, Printing, FISH, SYNTAX, Organic acid, Enzyme, Vaccine, Therapy, Workflow, DNA, ISH, PCR, Gene expression profiling, Hydrolysis, Genomics, CRO, Running, Automation, Fine chemical, Typesetting, Technology

The new kits are designed to accelerate assay development workflows in genomics, in particular for q/dPCR, NGS, ISH and FISH.

Key Points: 
  • The new kits are designed to accelerate assay development workflows in genomics, in particular for q/dPCR, NGS, ISH and FISH.
  • We see this product launch as a game-changer, enabling SYNTAX customers to be done with their assays before others have even started.
  • DNA Script presentations at AGBT include:
    Presenters: Ybert and DNA Script CTO and co-founder Xavier Godron, Ph.D.
  • By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.

DNA Script Appoints Chris Barbazette as Chief Commercial Officer

Retrieved on: 
Tuesday, May 10, 2022
Science, Other Science, Biotechnology, Research, Health, Technology, Genetics, Other Technology, Senior, Enzyme, SYNTAX, EDS, Organization, Affymetrix, Thermo Fisher Scientific, Synthetic biology, Chief commercial officer, DNA, Innovation, Genomics, Organic acid, Marketing, View, CEO, Technology, Research, Acquisition, Multimedia, Fine chemical, Management

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team.

Key Points: 
  • DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team.
  • View the full release here: https://www.businesswire.com/news/home/20220510005578/en/
    Chris Barbazette appointed Chief Commercial Officer of DNA Script (Photo: Business Wire)
    We are excited to welcome Chris to the DNA Script family, said CEO and co-founder Thomas Ybert.
  • I look forward to working with Chris as DNA Script continues to rapidly scale to meet demand for the SYNTAX Platform.
  • Barbazette joins DNA Script from Resolve Biosciences, an emerging leader in spatial biology, where he served as Chief Commercial Officer and established the German parent companys U.S. headquarters.

Ambulatory Surgery Centers Need a Tailored CVIS Platform

Retrieved on: 
Monday, April 18, 2022
Cardiology, Center, CEO, Data management, Ambulatory Surgery Center Association, DAIC, Center for Medicare and Medicaid Innovation, EMR, Ambulatory care, Surgical Care Affiliates, 3D ultrasound, Trauma, Hospital, SCAI, Functional endoscopic sinus surgery, Patient, Infection, CMS, Smartphone, Technology, Insurance, Health, Solution, Forecasting, ASC, Physician, SYNTAX, Risk, Centers for Medicare & Medicaid Services, Medicare, Comeau, Medical device, Health insurance, Medicine, Medical imaging, Pharmaceutical industry, Risk management

BOSTON, April 18, 2022 /PRNewswire-PRWeb/ -- For more than four decades, ambulatory surgery centers (ASCs) have offered patients the convenience of having certain surgical procedures performed outside the hospital setting.(1) By 2027, experts predict a 27.6% increase in the total number of ASCs; more than 50% of all procedures performed there will treat cardiovascular issues.(2) To handle increasing patient loads, cardiologists in these centers will need access to technology providing comprehensive data management throughout the entire care cycle. Dr. Serge Makowski, CEO and Co-founder of leading software design firm MediReport, says, "Moving certain cardiac procedures to an ASC provides many benefits. The patient receives the convenience and affordability of ambulatory care. The physicians benefit from more convenient scheduling and more autonomy. And the insurance companies benefit as ASCs offer the same procedures as hospitals but at a rate that is 35 to 50 percent less costly."

Key Points: 
  • BOSTON, April 18, 2022 /PRNewswire-PRWeb/ -- For more than four decades, ambulatory surgery centers (ASCs) have offered patients the convenience of having certain surgical procedures performed outside the hospital setting.
  • In 2019, the Centers for Medicare and Medicaid Services (CMS) updated their definition of surgery to include "surgery-like" procedures.
  • CardioReport Ambulatory offers a unified but flexible platform for the clinical team to perform their daily tasks in one single platform.
  • 2.Thompson D and Comeau C. "The Strategic Role of Ambulatory Surgery Centers Cardiology Care."

DNA Script Launches Early Access Program for Latest Advancements to the SYNTAX Platform and Enzymatic DNA Synthesis Technology

Retrieved on: 
Tuesday, April 12, 2022
Research, Other Health, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Science, Biotechnology, Health, Other Science, COVID-19, DNA, Organic acid, Imperial College London, Synthetic biology, Automation, Genetics, Scriptor Incertus, Printing, Research, Molecular biology, NGS, Organization, Program, BASE, Infection, Technology, Biological engineering, Vaccine, Biotin, AIBN, Enzyme, Assistant, SYNTAX, Industry, University, RNA transfection, View, EDS, Fine chemical, Nanotechnology

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of a new program for customers of their SYNTAX System, in which organizations receive early access to the latest advancements of their EDS technology.

Key Points: 
  • DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of a new program for customers of their SYNTAX System, in which organizations receive early access to the latest advancements of their EDS technology.
  • Dubbed the DNA Scriptors Early Access Program, its members already include the London Biofoundry and the BASE facility at the University of Queensland (UQ), Australia.
  • Being part of the DNA Scriptors Early Access Program provides access to this leading technology needed to speed the manufacture of mRNA vaccines.
  • The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System.

DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis

Retrieved on: 
Tuesday, April 5, 2022
Other Health, Research, Pharmaceutical, Hardware, Oncology, Technology, Infectious Diseases, Science, Biotechnology, FDA, Other Science, Health, EDS, Printing, DNA, APAC, Hazardous waste, Â, Cold, SYNTAX, Biotechnology, Research, NGS, Molecular biology, Sanger, Enzyme, Technology, Organic acid, CRISPR, Fine chemical, Aquaculture

These partnerships expand DNA Scripts worldwide footprint and provide sales and support for the SYNTAX DNA printing system in labs throughout the Asia-Pacific region.

Key Points: 
  • These partnerships expand DNA Scripts worldwide footprint and provide sales and support for the SYNTAX DNA printing system in labs throughout the Asia-Pacific region.
  • We are thrilled to welcome some of Asia-Pacifics leading life science distributors as key partners to build DNA Scripts global channel network, said DNA Script CEO and co-founder Thomas Ybert.
  • These partnerships represent an important step in DNA Scripts global commercial expansion and our commitment to support our Asia-Pacific customers research needs.
  • The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System.

Structured Cardiology Reporting in CVIS Platforms Key to Better Patient Care, Outcomes

Retrieved on: 
Monday, February 14, 2022
Angioplasty, Patient, SYNTAX, PACS, Time, CEO, Health, Documentation, HIS, American College, Society, Efficiency, American College of Cardiology, Cardiology, EMR, Cath, Hospital, Cath lab, Physician, Workflow, Diagnosis, Thrombosis, Report, Roadmap, Organization, Interventions, Medical imaging, Medical device, Pharmaceutical industry, Health insurance

However, most organizations don't take advantage of structured reporting, most cardiovascular information systems (CVIS) cannot effectively mine the wealth of data from a facility's cardiology department.

Key Points: 
  • However, most organizations don't take advantage of structured reporting, most cardiovascular information systems (CVIS) cannot effectively mine the wealth of data from a facility's cardiology department.
  • (1) It's estimated that only 10% of United States cardiac Cath labs use structured reporting to improve efficiency and bolster patient outcomes.
  • Structured reporting systems fully incorporate data, workflow, analytics, inventory management, billing, and process improvement in one central documentation system.
  • 1.Tierney, Mary C.; "Structured Reporting: The Road Map for Better Data, Workflow and Reports"; Cardiovascular Business, Accessed 08 Feb 2022; cardiovascularbusiness.com/sponsored/1170/topics/practice-management/structured-reporting-road-map-better-data-workflow-and-0.

DNA Script Joins Wellcome Leap R3 Program to Advance RNA Products and Therapies

Retrieved on: 
Wednesday, February 2, 2022
Health, Medical Devices, Genetics, Other Science, General Health, Science, Biotechnology, Sequence, DNA, Workflow, RNA transfection, Coalition, Technology, Research, SYNTAX, CEPI, Waste management, DNA synthesis, Program, EDS, Epidemic, Enzyme, Organic acid, Disrupt, Therapy, DGA, RNA, Coalition for Epidemic Preparedness Innovations, Vaccine, Moderna

DNA Script, a leader in Enzymatic DNA Synthesis (EDS) and DNA on demand, has inked a multi-million dollar, multi-year contract with Wellcome Leap to accelerate RNA products, including mRNA vaccines, and advance RNA therapies.

Key Points: 
  • DNA Script, a leader in Enzymatic DNA Synthesis (EDS) and DNA on demand, has inked a multi-million dollar, multi-year contract with Wellcome Leap to accelerate RNA products, including mRNA vaccines, and advance RNA therapies.
  • Under Wellcome Leaps RNA Response + Readiness (R3) program, DNA Script will work to develop a fully automated and deployable system to synthesize DNA templates for RNA production with a short turnaround time.
  • Wellcome Leaps R3 program, jointly funded with the Coalition for Epidemic Preparedness Innovations ( CEPI ), seeks to increase the development and deployment of RNA-based biologic products as a standardized platform technology with reduced cost.
  • By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.